In Q1 2026, Viemed Healthcare expanded its equipment and supply sales dramatically, primarily fueled by the Lehan acquisition and scaling PAP resupply programs, while healthcare staffing services saw a modest decline. The company's integrated home respiratory care model continues to drive patient outcomes across all 50 states, supported by a sizable licensed respiratory therapist workforce. Strategic growth hinges on further geographic expansion, women’s health product line growth, and clinical staffing increases, but regulatory oversight and reimbursement uncertainties remain material risks. Liquidity remains adequate with $9.8 million cash and manageable debt of $9.2 million as of March 31, 2026.